These are the stocks posting the largest moves before the bell.Market Insiderread more
Target beats second-quarter earnings expectations thanks to an increase in traffic and sales. The retailer also boosts its full-year estimates.Retailread more
Corporate debt recently passed the $1 trillion mark in a continuing sign of global financial displacement.Marketsread more
Trump said he has "been thinking about payroll taxes for a long time" — and he cautioned that "whether or not we do something now, it's not being done because of recession."Politicsread more
Lowe's also tops rival Home Depot on same-store sales growth in the U.S.Retailread more
President Donald Trump said on Twitter he was postponing a scheduled meeting with Denmark's prime minister because of her lack of interest in discussing a possible sale of...World Politicsread more
Dow to open higher; strong retail earnings; Gundlach says Fed lost control; negative-yielding corporate debt soars; and Trump on payroll tax cutMarketsread more
After a rush on refinances, homeowners took a breather last week, despite still seeing the lowest interest rates in about three years.Real Estateread more
Toni Sacconaghi said increased competition abroad is responsible for the weakness in Tesla's sales volume.Investingread more
The growing popularity of cocaine cut with fentanyl — known on the street as a speedball — or combinations of methamphetamine and fentanyl — known as a goofball — are driving...Health and Scienceread more
After Elon Musk touts Tesla solar on Twitter, Walmart sues the electric vehicle and clean energy company over store rooftop panels that ignited.Technologyread more
Merck on Tuesday reported second-quarter earnings and revenue that easily beat Wall Street's expectations and narrowed its earnings and revenue forecast for the year.
Share prices were up 0.8% in late morning.
Here's how the company did compared with what Wall Street expected:
The company expects full-year earnings per share between $4.84 and $4.94 versus the $4.75 a share Wall Street expects. It sees 2019 revenue coming between $45.2 billion and $46.2 billion. Wall Street was expecting revenue of $44.74 billion this year. Merck said the reduction in the earnings range reflects the inclusion of a charge of about $1.1 billion related to the acquisition of biotech firm Peloton Therapeutics, announced in May.
"Our science-led strategy and execution across our key growth pillars have driven another quarter of accelerating revenue growth with strength across our global portfolio," Chairman and CEO Ken Frazier said in the earnings release.
Merck said sales of Keytruda immunotherapy surged 58% in the quarter to $2.6 billion. Keytruda, which boosts the immune system to attack cancer, has driven growth for Merck and put pressure on Bristol-Myers Squibb's rival drug Opdivo.
Sales of Merck's Gardasil vaccine to prevent certain types of cancer were up 45.7% to $886 million. Sales of vaccines to children, which includes the company's MMR vaccine for measles, jumped 58% to $675 million.
The financial results come as the entire pharmaceutical market struggles amid scrutiny from the White House and Congress to lower prescription drugs costs. The SPDR S&P Pharmaceuticals XPH, an ETF that tracks the pharma industry's biggest companies, has increased roughly 3% year to date as of Monday's close, significantly lagging the S&P 500's 20% rise over the same period.